StockNews.com Begins Coverage on NovaBay Pharmaceuticals (NYSE:NBY)

StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report sent to investors on Monday. The firm issued a hold rating on the stock.

NovaBay Pharmaceuticals Trading Down 4.4 %

Shares of NBY opened at $0.60 on Monday. NovaBay Pharmaceuticals has a 12-month low of $0.36 and a 12-month high of $9.08. The company has a market cap of $3.19 million, a PE ratio of -0.01 and a beta of 0.73. The stock has a 50-day moving average price of $0.66 and a 200-day moving average price of $0.63.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.